NAD+

At a glance

---

What is NAD+?

First, the important distinction: NAD+ is not a peptide. It has no amino acids, no peptide bonds, and no sequence. It is a dinucleotide coenzyme — two nucleotides joined by a pyrophosphate linkage, one containing adenine and the other nicotinamide. We include it here because peptide clinics and longevity platforms routinely sell NAD+ therapy alongside peptide therapies, and consumers encounter it in the same space.^[1]

NAD+ stands for nicotinamide adenine dinucleotide, and the "+" indicates its oxidized form — the form ready to accept electrons. It was first identified in 1906 by Arthur Harden and William John Young, who discovered it as a heat-stable cofactor essential for yeast fermentation. They called it "cozymase." The Nobel Prize in Chemistry was awarded for this work in 1929.^[12]

NAD+ is not something exotic or novel. It is present in every cell of every living organism — from bacteria to humans. It is as fundamental to life as ATP. Your body synthesizes NAD+ continuously through multiple pathways, and it participates in hundreds of enzymatic reactions every second.

The therapeutic idea behind NAD+ supplementation is straightforward: NAD+ levels decline with age — by some estimates, up to 50% by middle age — and this decline is associated with many age-related problems. Restoring NAD+ to "youthful" levels might, in theory, improve cellular function. Whether that theory translates to meaningful clinical benefits is the central question.

---

How it works

In plain terms, NAD+ serves as a rechargeable battery in your cells. It shuttles electrons between chemical reactions, enabling your cells to convert food into energy, repair damaged DNA, and regulate gene expression. When NAD+ accepts electrons, it becomes NADH (the "charged" form). NADH then donates those electrons to produce ATP — the energy currency of the cell.^[1]

But NAD+ does far more than energy metabolism. It is also a critical signaling molecule consumed by three major classes of enzymes:

• Sirtuins — NAD+-dependent proteins that regulate gene expression, DNA repair, and mitochondrial function. Sirtuin activity depends directly on NAD+ availability.
• PARPs — DNA damage repair enzymes that consume NAD+ as they work. PARP1 alone may consume 80% of cellular NAD+ during intensive DNA repair.
• CD38 — An enzyme that increases with age and is now considered the primary driver of age-related NAD+ decline.

Why NAD+ declines with age (detailed)

The age-related decline in NAD+ is driven by three converging factors:^[3]

1. Increased CD38 expression: CD38 is a membrane-bound enzyme that degrades NAD+. Its levels rise substantially with age, driven partly by chronic low-grade inflammation ("inflammaging"). CD38 also degrades NMN (a NAD+ precursor), creating a double problem.

2. Increased PARP activation: As DNA damage accumulates with age, PARP enzymes consume more NAD+ for repair. This creates a "NAD+ drain" — the more damage your cells accumulate, the more NAD+ they burn through trying to fix it.

3. Decreased NAMPT expression: NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway (the main pathway for recycling NAD+). Its expression decreases with age, reducing the body's ability to regenerate NAD+.

The result: supply drops while demand increases. This is the core biological rationale for NAD+ supplementation — and it is scientifically sound. The question is whether raising NAD+ levels from the outside produces the same benefits as the youthful levels your body maintained naturally.

How different NAD+-boosting strategies work

Not all NAD+ delivery methods are equal, and the evidence differs substantially:

Approach	How it works	Evidence
IV NAD+	Direct infusion into bloodstream	Most expensive, most marketed, least evidence. Whether IV NAD+ actually enters cells in meaningful amounts (vs. being broken down extracellularly by CD38) is debated.
Subcutaneous NAD+ injection	Slower absorption than IV	Same bioavailability questions. Growing telehealth market.
NR (Nicotinamide Riboside)	Oral precursor; enters cells and is converted to NMN, then NAD+	Most human trial data of any NAD+ strategy. Proven to raise blood NAD+ levels.
NMN (Nicotinamide Mononucleotide)	Oral precursor; one step closer to NAD+ in the salvage pathway	Growing human trial data. Raises blood NAD+.
Niacin (Nicotinic acid)	Oldest NAD+ precursor; Preiss-Handler pathway	Proven to raise NAD+. Causes flushing. FDA-approved for dyslipidemia.

The irony: the cheapest delivery methods (oral NR and NMN) have more clinical trial evidence than the most expensive one (IV NAD+).

---

What the research says

The basic science of NAD+ is robust and compelling. But a 2024 systematic review concluded that "NAD+ supplementation lacks clinical evidence for therapeutic benefits in humans" and "injectable NAD+ has no guideline support." The most expensive form of NAD+ therapy has the least evidence.

Research timeline

NAD+ has one of the longest research histories of any molecule in the longevity space — over a century of scientific study:

Human clinical trials

The human evidence picture for NAD+ is more nuanced than for most compounds on this site, because the evidence differs dramatically depending on which form you're asking about. Here is a critical distinction that most NAD+ marketing materials blur:

Notice what is absent from this list: any controlled trial of IV NAD+ for any indication. The most expensive, most marketed form of NAD+ therapy has the weakest evidence base. This is not an oversight — the data simply does not exist yet.

Basic science

The basic science of NAD+ is genuinely impressive — this is not a fringe molecule with speculative mechanisms. NAD+ has been studied for over a century, and its biochemistry is textbook-level established.^[1]

Key established findings

• Metabolic role: NAD+ participates in over 500 enzymatic reactions. It is essential for glycolysis, the TCA cycle, and oxidative phosphorylation. Without NAD+, cellular energy production stops.
• Age-related decline: Consistently demonstrated in human studies across multiple tissues — blood, skin, liver, muscle, and brain. The decline is real and well-documented.^[3]
• Sirtuin regulation: NAD+ is the required cofactor for all seven human sirtuins (SIRT1-7). Sirtuins regulate gene expression, DNA repair, mitochondrial biogenesis, inflammation, and circadian rhythm.
• DNA repair: PARPs consume NAD+ to repair DNA damage. Maintaining NAD+ pools supports the DNA damage response.
• Alzheimer's research: A 2025 study in Science Advances showed NAD+ augmentation corrected alternative splicing events relevant to Alzheimer's disease via the EVA1C protein in mouse models.^[10]
• Blood levels can be raised: Multiple human RCTs confirm that oral NR and NMN reliably increase blood NAD+ and related metabolites.

---

What the evidence shows

NAD+ marketing tends to blur the line between established biochemistry and clinical evidence. Here's what the published research actually supports for the most common claims:

---

Safety & side effects

Oral precursors (NR and NMN)

The safety profile for oral NR and NMN is the best-characterized of any NAD+-boosting strategy:^[9]

• NMN at 100-1,250 mg/day has shown no serious adverse events in trials up to 12 weeks
• NR at 300-2,000 mg/day has been well tolerated across multiple RCTs
• Common side effects: mild GI discomfort, headaches at higher doses, niacin-like flushing
• A 2024 systematic review concluded that NAD+ precursor supplementation is "safe" based on current data, but long-term studies in large cohorts are lacking

IV NAD+

IV NAD+ has no controlled safety trials but extensive anecdotal reporting. Commonly reported effects during infusion include:

• Nausea (very common, dose and rate-dependent)
• Chest tightness or pressure
• Flushing and warmth
• Headache
• Abdominal cramping
• Muscle cramping
• Light-headedness and dizziness
• Anxiety and a "sense of impending doom"

Most of these effects are managed by slowing the infusion rate, which is why IV NAD+ sessions typically run 2-4 hours.

The compounding quality problem

Theoretical risks

Cancer concern and drug interactions

Cancer concern: NAD+ fuels cellular metabolism broadly — including cancer cells. Rapidly increasing NAD+ could theoretically support tumor growth or help cancer cells resist metabolic stress. Preclinical evidence is mixed; some studies show NAD+ boosting is protective, others suggest it could fuel existing cancers. No human evidence of harm exists, but the theoretical concern is legitimate and under-discussed in marketing materials.

PARP inhibitor interaction: Cancer patients on PARP inhibitors (olaparib, niraparib, etc.) should not take NAD+ supplements. NAD+ could counteract the drug's mechanism — PARP inhibitors work by exploiting cancer cells' reliance on PARP-mediated repair, and adding NAD+ could undermine this therapeutic strategy.

Other theoretical contraindications:

• Active malignancy (theoretical concern about fueling cancer metabolism)
• Cardiovascular disease / hypotension for IV (risk of fluid overload and hemodynamic effects)
• Pregnancy / breastfeeding (no safety data)
• Patients on MAO inhibitors
• Immunosuppressants (unknown interactions with NAD+-dependent immune pathways)

---

How people use it

NAD+ therapy spans three distinct market tiers — and the relationship between price and evidence is inverted:

Administration routes

• IV infusion ($250-$1,500 per session): The premium tier. Sessions run 2-4 hours with slow infusion to manage side effects. The most expensive option and the one with the least clinical evidence.
• Subcutaneous injection ($100-$400/month): Growing telehealth market. Same bioavailability questions as IV. Injection site reactions are common.
• Oral NR supplements ($40-$60/month): The most studied delivery method. ChromaDex's Tru Niagen has NDI notification and GRAS status.
• Oral NMN supplements ($30-$80/month): Growing trial data. Widely available over the counter.

The price-evidence inversion

This is worth stating plainly: the cheapest options (oral NR and NMN supplements at $30-$60/month) have the most clinical trial data. The most expensive option (IV NAD+ at $250-$1,500 per session) has essentially none. The marketing claim that "you need IV NAD+ because oral precursors don't work" is not supported by any published clinical comparison.

Oral NR and NMN have been shown in multiple RCTs to raise blood NAD+ levels. IV NAD+ raises blood levels too — but whether IV NAD+ actually enters cells in meaningful amounts (rather than being degraded extracellularly by CD38) is an open scientific question.

Common stacking context

In clinic and community practice, NAD+ is often combined with:

• Resveratrol — Sirtuin activator; the David Sinclair protocol combines it with NMN. Limited human evidence for the combination.
• Trimethylglycine (TMG) — NAD+ metabolism consumes methyl groups; TMG provides methyl donors. Theoretical rationale, no clinical trials.
• Glutathione — Often added to IV NAD+ infusions. No evidence for synergy.
• Quercetin / Fisetin — Potential CD38 inhibitors (reduce NAD+ consumption). Preclinical evidence only.

All combination protocols are community-derived or practitioner-recommended and have not been studied in controlled settings.

---

Legal & regulatory status

As of March 2026:

FDA status

NAD+ is not FDA-approved as a drug for any indication. Unlike BPC-157 and several other peptides, NAD+ was not placed on the FDA's Category 2 restricted list. It remains eligible for compounding under 503A/503B pathways with a valid prescription.

However, the FDA has expressed concerns about compounding quality. In October 2025, the agency classified a Class I recall for a compounded NAD+ injection product due to elevated endotoxin levels — the most serious recall classification.^[13]

Supplement status

• NR (as Niagen, ChromaDex) has New Dietary Ingredient (NDI) notification and GRAS (Generally Recognized as Safe) status. The most regulatory-validated NAD+ precursor.
• NMN is widely sold as a dietary supplement. Its regulatory status was briefly challenged when the FDA questioned whether NMN could be sold as a supplement after it entered clinical trials as an investigational drug (2022-2023). NMN supplements remain widely available.

WADA / USADA status

NAD+, NMN, and NR are not prohibited by WADA. They are not on the Prohibited List. Athletes should use third-party tested products (NSF for Sport, Informed Choice) to avoid contamination with banned substances.

---

How IV NAD+ compares to oral precursors

The most important comparison for consumers isn't NAD+ vs. another compound — it's the different delivery methods for NAD+ itself:

The contrast is worth reflecting on. The supplement form that anyone can buy for $40/month has been studied in multiple randomized controlled trials and has a reasonable safety profile. The clinic form that costs $250-$1,500 per session and requires 2-4 hours in a chair has zero controlled trials. The evidence doesn't support the premium pricing — at least not yet.

This doesn't mean IV NAD+ cannot work. It means the data to justify the cost and inconvenience does not currently exist.

---

References

1. [1]

   Covarrubias AJ, Perrone R, Grozio A, Verdin E. “NAD+ metabolism and its roles in cellular processes during ageing.” Nat Rev Mol Cell Biol. 2021. 22(2):119–141 DOI PubMedReview

   Comprehensive review of NAD+ biology and its role in aging. Foundational reference for understanding NAD+ decline.

2. [2]

   Rajman L, Chwalek K, Sinclair DA. “Therapeutic potential of NAD-boosting molecules: the in vivo evidence.” Cell Metab. 2018. 27(3):529–547 DOI PubMedReview

   Major review of in vivo evidence for NAD+ boosting across organ systems.

3. [3]

   Camacho-Pereira J, Tarragó MG, Chini CCS, et al.. “CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism.” Cell Metab. 2016. 23(6):1127–1139 DOI PubMedAnimal study

   Landmark paper establishing CD38 as a primary driver of age-related NAD+ decline.

4. [4]

   Morifuji M, et al.. “Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults.” Geroscience. 2024. 46(5):4671–4688 DOI PubMedRCT

   Double-blind RCT with 60 older adults (65–75 years). 250 mg/day NMN for 12 weeks. Industry-sponsored (Meiji Holdings).

5. [5]

   Massachusetts General Hospital / Harvard Medical School investigators. “Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial.” eClinicalMedicine (Lancet). 2025. DOI PubMedRCT

   Double-blind, placebo-controlled. 2,000 mg/day NR. Showed brain NAD+ increases and reduced inflammatory cytokines.

6. [6]

   Multiple authors. “Effects of nicotinamide mononucleotide supplementation on muscle and liver functions among the middle-aged and elderly: a systematic review and meta-analysis of randomized controlled trials.” 2024. PubMedSystematic review

   Meta-analysis of 9 RCTs with 412 participants. Positive effects on muscle mass and gait speed.

7. [7]

   Multiple authors. “Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis.” Crit Rev Food Sci Nutr. 2024. PubMedSystematic review

   12 studies, 513 participants. NMN raised blood NAD+ significantly, but most metabolic endpoints showed no significant differences vs. control.

8. [8]

   Multiple authors. “A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.” Geroscience. 2024. PubMedPilot study

   Pilot study with 20 subjects. Dose escalation to 1 g/day NR over 10 weeks. Safety and tolerability focus.

9. [9]

   Multiple authors. “Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.” Am J Physiol Endocrinol Metab. 2024. PubMedSystematic review

   Concluded that 'NAD+ supplementation lacks clinical evidence for therapeutic benefits in humans' and 'injectable NAD+ has no guideline support.'

10. [10]

    Multiple authors. “NAD+ reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C.” Science Advances. 2025. 11(45):eady9811 DOI PubMedAnimal study

    Preclinical study demonstrating NAD+ augmentation corrects splicing events via EVA1C in Alzheimer’s models. Clinical trials ongoing.

11. [11]

    Multiple authors. “Clinical evidence for targeting NAD therapeutically.” Pharmaceuticals. 2020. 13(9):247 PubMedReview
12. [12]

    Harden A, Young WJ. “The alcoholic ferment of yeast-juice.” Proc R Soc Lond B. 1906. 78:369–375

    The foundational paper describing the discovery of NAD+ (then called 'cozymase'). Nobel Prize in Chemistry awarded to Harden and von Euler-Chelpin in 1929.

13. [13]

    U.S. Food and Drug Administration. “Class I Recall — NAD+ for Injection (GenoGenix LLC, elevated endotoxin levels).” 2025. Link

    Class I recall (most serious level) initiated July 2025, classified October 2025. Lot #GG121624-023. Elevated endotoxin levels in compounded NAD+ injection product.

14. [14]

    Multiple authors. “The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis.” J Cachexia Sarcopenia Muscle. 2025. PubMedSystematic review

    Most recent meta-analysis. Found current evidence does not conclusively support NMN/NR for preserving muscle mass and function in adults over 60.

---